Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas

Wen Jiang; Paul D. Chamberlain; Adam S. Garden; Betty Y.S. Kim; Dominic Ma; Emily J. Lo; Diana Bell; G. Brandon Gunn; Clifton D. Fuller; David I. Rosenthal; Beth M. Beadle; Steven J. Frank; William H. Morrison; Adel K. El-Naggar; Bonnie S. Glisson; Erich M. Sturgis; Jack Phan

doi:10.1002/hed.24258

Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas

Wen Jiang, Paul D. Chamberlain, Adam S. Garden, Betty Y.S. Kim, Dominic Ma, Emily J. Lo, Diana Bell, G. Brandon Gunn, Clifton D. Fuller, David I. Rosenthal, Beth M. Beadle, Steven J. Frank, William H. Morrison, Adel K. El-Naggar, Bonnie S. Glisson, Erich M. Sturgis, Jack Phan

Research output: Contribution to journal › Article › peer-review

25 Scopus citations

Abstract

Background Overexpression of p16 is associated with improved outcomes among patients with oropharyngeal carcinoma. However, its role in the outcomes of patients with nasopharyngeal cancer (NPC) remains unclear. Methods Eighty-six patients with NPC treated at MD Anderson Cancer Center from 2000 to 2014 were identified. Epstein-Barr virus (EBV) and human papillomavirus (HPV) status were determined by in situ hybridization (ISH) and p16 by immunohistochemical staining. Results EBV positivity was associated with extended overall survival (OS; median, 95.0 vs 44.9 months; p <.004), progression-free survival (PFS; median, 80.4 vs 28.1 months; p <.013), and locoregional control (median, 104.4 vs 65.5 months; p <.043). In patients with EBV-positive tumors, p16 overexpression correlated with improved PFS (median, 106.3 vs 27.1 months; p <.02) and locoregional control (median, 93.6 vs 64.5 months; p <.02). Conclusion P16 overexpression is associated with improved PFS and locoregional control in patients with EBV-positive NPC. P16 expression may complement EBV status in predicting treatment outcomes for patients with NPC.

Original language	English (US)
Pages (from-to)	E1459-E1466
Journal	Head and Neck
Volume	38
DOIs	https://doi.org/10.1002/hed.24258
State	Published - Apr 1 2016
Externally published	Yes

Keywords

Epstein-Barr virus (EBV)
human papillomavirus (HPV)
nasopharyngeal cancer
nasopharyngeal carcinoma
p16

ASJC Scopus subject areas

Otorhinolaryngology

Access to Document

10.1002/hed.24258

Cite this

Jiang, W., Chamberlain, P. D., Garden, A. S., Kim, B. Y. S., Ma, D., Lo, E. J., Bell, D., Gunn, G. B., Fuller, C. D., Rosenthal, D. I., Beadle, B. M., Frank, S. J., Morrison, W. H., El-Naggar, A. K., Glisson, B. S., Sturgis, E. M., & Phan, J. (2016). Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. Head and Neck, 38, E1459-E1466. https://doi.org/10.1002/hed.24258

Jiang, W, Chamberlain, PD, Garden, AS, Kim, BYS, Ma, D, Lo, EJ, Bell, D, Gunn, GB, Fuller, CD, Rosenthal, DI, Beadle, BM, Frank, SJ, Morrison, WH, El-Naggar, AK, Glisson, BS, Sturgis, EM & Phan, J 2016, 'Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas', Head and Neck, vol. 38, pp. E1459-E1466. https://doi.org/10.1002/hed.24258

@article{f349f33857d04732b27606c4fad78548,

title = "Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas",

abstract = "Background Overexpression of p16 is associated with improved outcomes among patients with oropharyngeal carcinoma. However, its role in the outcomes of patients with nasopharyngeal cancer (NPC) remains unclear. Methods Eighty-six patients with NPC treated at MD Anderson Cancer Center from 2000 to 2014 were identified. Epstein-Barr virus (EBV) and human papillomavirus (HPV) status were determined by in situ hybridization (ISH) and p16 by immunohistochemical staining. Results EBV positivity was associated with extended overall survival (OS; median, 95.0 vs 44.9 months; p <.004), progression-free survival (PFS; median, 80.4 vs 28.1 months; p <.013), and locoregional control (median, 104.4 vs 65.5 months; p <.043). In patients with EBV-positive tumors, p16 overexpression correlated with improved PFS (median, 106.3 vs 27.1 months; p <.02) and locoregional control (median, 93.6 vs 64.5 months; p <.02). Conclusion P16 overexpression is associated with improved PFS and locoregional control in patients with EBV-positive NPC. P16 expression may complement EBV status in predicting treatment outcomes for patients with NPC.",

keywords = "Epstein-Barr virus (EBV), human papillomavirus (HPV), nasopharyngeal cancer, nasopharyngeal carcinoma, p16",

author = "Wen Jiang and Chamberlain, {Paul D.} and Garden, {Adam S.} and Kim, {Betty Y.S.} and Dominic Ma and Lo, {Emily J.} and Diana Bell and Gunn, {G. Brandon} and Fuller, {Clifton D.} and Rosenthal, {David I.} and Beadle, {Beth M.} and Frank, {Steven J.} and Morrison, {William H.} and El-Naggar, {Adel K.} and Glisson, {Bonnie S.} and Sturgis, {Erich M.} and Jack Phan",

note = "Publisher Copyright: {\textcopyright} 2015 Wiley Periodicals, Inc..",

year = "2016",

month = apr,

day = "1",

doi = "10.1002/hed.24258",

language = "English (US)",

volume = "38",

pages = "E1459--E1466",

journal = "Head and Neck",

issn = "1043-3074",

publisher = "Wiley-Liss Inc.",

}

TY - JOUR

T1 - Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas

AU - Jiang, Wen

AU - Chamberlain, Paul D.

AU - Garden, Adam S.

AU - Kim, Betty Y.S.

AU - Ma, Dominic

AU - Lo, Emily J.

AU - Bell, Diana

AU - Gunn, G. Brandon

AU - Fuller, Clifton D.

AU - Rosenthal, David I.

AU - Beadle, Beth M.

AU - Frank, Steven J.

AU - Morrison, William H.

AU - El-Naggar, Adel K.

AU - Glisson, Bonnie S.

AU - Sturgis, Erich M.

AU - Phan, Jack

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Background Overexpression of p16 is associated with improved outcomes among patients with oropharyngeal carcinoma. However, its role in the outcomes of patients with nasopharyngeal cancer (NPC) remains unclear. Methods Eighty-six patients with NPC treated at MD Anderson Cancer Center from 2000 to 2014 were identified. Epstein-Barr virus (EBV) and human papillomavirus (HPV) status were determined by in situ hybridization (ISH) and p16 by immunohistochemical staining. Results EBV positivity was associated with extended overall survival (OS; median, 95.0 vs 44.9 months; p <.004), progression-free survival (PFS; median, 80.4 vs 28.1 months; p <.013), and locoregional control (median, 104.4 vs 65.5 months; p <.043). In patients with EBV-positive tumors, p16 overexpression correlated with improved PFS (median, 106.3 vs 27.1 months; p <.02) and locoregional control (median, 93.6 vs 64.5 months; p <.02). Conclusion P16 overexpression is associated with improved PFS and locoregional control in patients with EBV-positive NPC. P16 expression may complement EBV status in predicting treatment outcomes for patients with NPC.

AB - Background Overexpression of p16 is associated with improved outcomes among patients with oropharyngeal carcinoma. However, its role in the outcomes of patients with nasopharyngeal cancer (NPC) remains unclear. Methods Eighty-six patients with NPC treated at MD Anderson Cancer Center from 2000 to 2014 were identified. Epstein-Barr virus (EBV) and human papillomavirus (HPV) status were determined by in situ hybridization (ISH) and p16 by immunohistochemical staining. Results EBV positivity was associated with extended overall survival (OS; median, 95.0 vs 44.9 months; p <.004), progression-free survival (PFS; median, 80.4 vs 28.1 months; p <.013), and locoregional control (median, 104.4 vs 65.5 months; p <.043). In patients with EBV-positive tumors, p16 overexpression correlated with improved PFS (median, 106.3 vs 27.1 months; p <.02) and locoregional control (median, 93.6 vs 64.5 months; p <.02). Conclusion P16 overexpression is associated with improved PFS and locoregional control in patients with EBV-positive NPC. P16 expression may complement EBV status in predicting treatment outcomes for patients with NPC.

KW - Epstein-Barr virus (EBV)

KW - human papillomavirus (HPV)

KW - nasopharyngeal cancer

KW - nasopharyngeal carcinoma

KW - p16

UR - http://www.scopus.com/inward/record.url?scp=84948179083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84948179083&partnerID=8YFLogxK

U2 - 10.1002/hed.24258

DO - 10.1002/hed.24258

M3 - Article

C2 - 26560893

AN - SCOPUS:84948179083

SN - 1043-3074

VL - 38

SP - E1459-E1466

JO - Head and Neck

JF - Head and Neck

ER -

Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this